BMS, Pfizer win patent dispute over blockbuster drug, Eliquis

06-09-2021

Muireann Bolger

BMS, Pfizer win patent dispute over blockbuster drug, Eliquis

nitpicker / Shutterstock.com

In a victory for Bristol-Myers Squibb and Pfizer, the US Court of Appeals for the Federal Circuit has affirmed the validity of a pair of patents covering blood clot treatment, Eliquis (apixaban).


BMS, Pfizer, patent, Eliquis, generics, big pharma

LSIPR